These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 14982152)

  • 21. Applications of physiologically based absorption models in drug discovery and development.
    Parrott N; Lave T
    Mol Pharm; 2008; 5(5):760-75. PubMed ID: 18547054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Applications of high-throughput ADME in drug discovery.
    Kassel DB
    Curr Opin Chem Biol; 2004 Jun; 8(3):339-45. PubMed ID: 15183334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Scientific and regulatory perspectives on metabolizing enzyme-transporter interplay and its role in drug interactions: challenges in predicting drug interactions.
    Zhang L; Zhang Y; Huang SM
    Mol Pharm; 2009; 6(6):1766-74. PubMed ID: 19839641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [How to identify and prevent pharmacokinetically relevant drug-drug interactions].
    Ritter CA
    Med Monatsschr Pharm; 2009 Oct; 32(10):364-74; quiz 375-6. PubMed ID: 19886226
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism.
    Baillie TA
    Chem Res Toxicol; 2008 Jan; 21(1):129-37. PubMed ID: 18052111
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, data analysis, and simulation of in vitro drug transport kinetic experiments using a mechanistic in vitro model.
    Poirier A; Lavé T; Portmann R; Brun ME; Senner F; Kansy M; Grimm HP; Funk C
    Drug Metab Dispos; 2008 Dec; 36(12):2434-44. PubMed ID: 18809732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A combined approach to drug metabolism and toxicity assessment.
    Ekins S; Andreyev S; Ryabov A; Kirillov E; Rakhmatulin EA; Sorokina S; Bugrim A; Nikolskaya T
    Drug Metab Dispos; 2006 Mar; 34(3):495-503. PubMed ID: 16381662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm.
    Ito K; Hallifax D; Obach RS; Houston JB
    Drug Metab Dispos; 2005 Jun; 33(6):837-44. PubMed ID: 15897600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug transporter and cytochrome P450 mRNA expression in human ocular barriers: implications for ocular drug disposition.
    Zhang T; Xiang CD; Gale D; Carreiro S; Wu EY; Zhang EY
    Drug Metab Dispos; 2008 Jul; 36(7):1300-7. PubMed ID: 18411399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytochrome P450-mediated metabolism in the human gut wall.
    Thelen K; Dressman JB
    J Pharm Pharmacol; 2009 May; 61(5):541-58. PubMed ID: 19405992
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive ADMET studies, the challenges and the opportunities.
    Davis AM; Riley RJ
    Curr Opin Chem Biol; 2004 Aug; 8(4):378-86. PubMed ID: 15288247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toward in silico structure-based ADMET prediction in drug discovery.
    Moroy G; Martiny VY; Vayer P; Villoutreix BO; Miteva MA
    Drug Discov Today; 2012 Jan; 17(1-2):44-55. PubMed ID: 22056716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transporters--the view from industry.
    Kohl C
    Chem Biodivers; 2009 Nov; 6(11):1988-99. PubMed ID: 19937835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Designing better drugs: predicting cytochrome P450 metabolism.
    de Groot MJ
    Drug Discov Today; 2006 Jul; 11(13-14):601-6. PubMed ID: 16793528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estimating human drug oral absorption kinetics from Caco-2 permeability using an absorption-disposition model: model development and evaluation and derivation of analytical solutions for k(a) and F(a).
    Usansky HH; Sinko PJ
    J Pharmacol Exp Ther; 2005 Jul; 314(1):391-9. PubMed ID: 15833900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transporters and drug therapy: implications for drug disposition and disease.
    Ho RH; Kim RB
    Clin Pharmacol Ther; 2005 Sep; 78(3):260-77. PubMed ID: 16153397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mice as clinically relevant models for the study of cytochrome P450-dependent metabolism.
    Muruganandan S; Sinal CJ
    Clin Pharmacol Ther; 2008 Jun; 83(6):818-28. PubMed ID: 18388875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro ADME phenotyping in drug discovery: current challenges and future solutions.
    Williams JA; Bauman J; Cai H; Conlon K; Hansel S; Hurst S; Sadagopan N; Tugnait M; Zhang L; Sahi J
    Curr Opin Drug Discov Devel; 2005 Jan; 8(1):78-88. PubMed ID: 15679175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of recent innovations in the use of liquid chromatography-mass spectrometry in support of drug metabolism studies: are we all the way there yet?
    Nassar AE; Talaat RE; Kamel AM
    Curr Opin Drug Discov Devel; 2006 Jan; 9(1):61-74. PubMed ID: 16445118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surgical and pharmacological animal models used in drug metabolism and pharmacokinetics.
    Landskroner KA; Hess P; Treiber A
    Xenobiotica; 2011 Aug; 41(8):687-700. PubMed ID: 21486193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.